cu-ghk | C14H24CuN6O4 | CID 378611 and rejuvenate with GHK Dermicu™ GHK-Cu Facial Serum

Common effects: Injection-site reactions (mild redness, slight discomfort) most common Transient headaches (resolved without intervention) Mild fatigue in some subjects (usually early in treatment) No serious adverse events reported Laboratory changes: No significant changes in blood glucose or insulin levels No effects on liver enzymes or kidney function No changes in IGF-1 levels (confirming the absence of a GH rise) No clinically significant changes in other laboratory parameters Phase 2 trials (overweight/obese subjects): Efficacy trials in overweight and obese populations confirmed the favorable safety profile

Furthermore, both compounds have demonstrated anti-inflammatory properties, albeit through different mechanisms

Best for patients consolidating their health spend onto the single highest-evidence therapy

The presence of sialo glycoproteins and sialo glycolipids also gives the BBB surface a negative charge